Reference : In vitro and in vivo activity of the nuclear factor-kappa B inhibitor sulfasalazine i...
Scientific journals : Article
Human health sciences : Neurology
http://hdl.handle.net/2268/61896
In vitro and in vivo activity of the nuclear factor-kappa B inhibitor sulfasalazine in human glioblastomas.
English
Robe, Pierre [Centre Hospitalier Universitaire de Liège - CHU > > Neurochirurgie >]
Bentires-Alj, Mohamed [Centre Hospitalier Universitaire de Liège - CHU > Center for Cellular and Molecular Therapeutics > > >]
Bonif, Marianne [Centre Hospitalier Universitaire de Liège - CHU > Center for Cellular and Molecular Therapeutics > > >]
Rogister, Bernard [Centre Hospitalier Universitaire de Liège - CHU > > Neurologie Sart Tilman >]
Deprez, Manuel [Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques >]
Haddada, Heddi [Institut Gustave-Roussy, Villejuif, France > Unite´ INSERM 487 > > >]
Khac, Minh-Tuan Nguyen [Centre Hospitalier Universitaire de Liège - CHU > Center for Cellular and Molecular Therapeutics > > >]
Jolois, Olivier mailto [Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Histologie humaine >]
Erkmen, Kadir [Children’s Hospital, Harvard Medical School, Boston > Department of Neurosurgery > > >]
Merville, Marie-Paule [Université de Liège - ULiège > Département de pharmacie > Chimie médicale >]
Black, Peter M [Children’s Hospital, Harvard Medical School, Boston > Department of Neurosurgery > > >]
Bours, Vincent mailto [Centre Hospitalier Universitaire de Liège - CHU > > Génétique >]
2004
Clinical Cancer Research : An Official Journal of the American Association for Cancer Research
American Association for Cancer Research, Inc. (AACR)
10
16
5595-603
Yes (verified by ORBi)
International
1078-0432
Birmingham
AL
[en] Anti-Inflammatory Agents, Non-Steroidal/toxicity ; Antineoplastic Agents ; Brain Neoplasms/drug therapy/pathology ; Cell Line, Tumor ; Gene Therapy ; Glioblastoma/drug therapy/pathology ; Humans ; NF-kappa B/antagonists & inhibitors ; Sulfasalazine/toxicity ; Tumor Cells, Cultured
[en] Glioblastomas, the most common primary brain cancers, respond poorly to current treatment modalities and carry a dismal prognosis. In this study, we demonstrated that the transcription factor nuclear factor (NF)-kappaB is constitutively activated in glioblastoma surgical samples, primary cultures, and cell lines and promotes their growth and survival. Sulfasalazine, an anti-inflammatory drug that specifically inhibits the activation of NF-kappaB, blocked the cell cycle and induced apoptosis in several glioblastoma cell lines and primary cultures, as did gene therapy with a vector encoding a super-repressor of NF-kappaB. In vivo, sulfasalazine also significantly inhibited the growth of experimental human glioblastomas in nude mice brains. Given the documented safety of sulfasalazine in humans, these results may lead the way to a new class of glioma treatment.
Researchers ; Professionals
http://hdl.handle.net/2268/61896
10.1158/1078-0432.CCR-03-0392
Must link to the publisher PDF of article on journal website http://www.aacr.org/ subject to Restrictions below, author can archive post-print (ie final draft post-refereeing)
Restrictions:
* 12 months embargo

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas.pdfNo commentaryAuthor postprint1.45 MBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.